Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma

BMC Clinical Pathology

Alessandro D Santin¹  Dana M Roque¹  Sergio Pecorelli³  Enrico Sartori³  Fabio Facchetti⁴  Renata A Tassi³  Elisabetta Bandiera³  Paola Todeschini³  Chiara Romani³  Antonella Ravaggi³  Silvia Lonardi⁴  Marcella Falchetti⁴  Stefano Calza²  Laura Zanotti³  Eliana Bignotti³ 

[1] Department of Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177, Stockholm, Sweden;“Angelo Nocivelli” Institute of Molecular Medicine, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123, Brescia, Italy;Department of Pathology, University of Brescia, Viale Europa 11, 25123, Brescia, Italy

关键词: Prognostic factor;    Tissue microarrays;    TACSTD2;    Trop-2;    Endometrioid endometrial cancer;   

Others  :  1085222
DOI  :  10.1186/1472-6890-12-22

 received in 2012-06-12, accepted in 2012-11-07,  发布年份 2012

【 摘 要 】

Background

Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially overexpressed relative to normal tissue in a variety of human adenocarcinomas, including endometrioid endometrial carcinomas (EEC). Trop-2 overexpression has been proposed as a marker for biologically aggressive tumor phenotypes.

Methods

Trop-2 protein expression was quantified using tissue microarrays consisting of formalin-fixed paraffin-embedded specimens from 118 patients who underwent surgical staging from 2001–9 by laparotomy for EEC. Clinicopathologic characteristics including age, stage, grade, lymphovascular space invasion, and medical comorbidities were correlated with immunostaining score. Univariate and multivariate analyses were performed for overall survival, disease-free survival, and progression-free survival in relation to clinical parameters and Trop-2 protein expression.

Results

Clinical outcome data were available for 103 patients. Strong Trop-2 immunostaining was significantly associated with higher tumor grade (p=0.02) and cervical involvement (p<0.01). Univariate analyses showed a significant association with reduced disease-free survival (DFS) (p=0.01), and a trend towards significance for overall and progression-free survival (p=0.06 and p=0.05, respectively). Multivariate analyses revealed Trop-2 overexpression and advanced FIGO stage to be independent prognostic factors for poor DFS (p=0.04 and p <0.001, respectively).

Conclusions

Trop-2 protein overexpression is significantly associated with higher tumor grade and serves as an independent prognostic factor for DFS in endometrioid endometrial cancer.

【 授权许可】

   
2012 Bignotti et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics-2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Bohkman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15(1):10-17.
• [3]Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I: Endometrial cancer. Lancet 2005, 366:491-505.
• [4]Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F: Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010, 21:1851-1856.
• [5]Sherman ME: Theories of endometrial carcinogenesis. Mod Pathol 2000, 13(3):295-298.
• [6]Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006, 24(29):4783-4791.
• [7]Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE: Uterine papillary serous carcinoma: pattern of metastatic spread. Gynecol Oncol 1994, 54:264-268.
• [8]Creasman W, Kohler M, Odicino , Maisonneuve P, Boyle P: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004, 95:593-596.
• [9]Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L: The frequency of p53, K-Ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma−evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
• [10]Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S: Determination of Her2/Neu status in uterine serous papillary carcinoma:comparative analysis of immunohistochemistry and fluorescence is situ hybridization. Gynecol Oncol 2005, 98:24-30.
• [11]Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S: Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005, 104:1391-7.
• [12]Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón Y, Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J: Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol 2011.
• [13]Lipinski M, Parks DR, Rouse RV, Herzenberg LA: Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci 1981, 78:5147-5150.
• [14]Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI: Characterization of human ovarian carcinoma-associated antigens defined by monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987, 39:297-303.
• [15]Alberti S, Miotti S, Stella M, Klein CE, Fornaro M, Menard S, Colnaghi MI: Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 1992, 50:1330-1336.
• [16]Stein R, Basu A, Chen S, Shih LB, Goldenberg DM: Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 1993, 55:938-496.
• [17]Zhang I, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 1997, 276:1268-7122.
• [18]Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH: Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002, 160:1239-1249.
• [19]Nakashima K, Shimada H, Ochai T, Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi M, Hiwasa T: Serological identification of Trop-2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004, 112:1029-1035.
• [20]Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF: Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005, 54:374-384.
• [21]Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Godken M, Dunn D, Roman JJ, O’Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004, 112(1):14-25.
• [22]Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 2011, 117:3163-3172.
• [23]Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol 2011, 122:171-177.
• [24]Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD: Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for therapy with hRS7, a humanized anti-Trop-2monoclonal antibody. Int J Gynecol Cancer 2011, 21:1613-1621.
• [25]Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD: Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol 2011, 205:567.e1-567.e7.
• [26]Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD: Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-rop-2 antibody. J Exp Clin Cancer Res 2011, 30:106-112. BioMed Central Full Text
• [27]Esselen KM, Boruta DM, del Carmen M, Schorge JO, Goodman A, Growdon WB: Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review. Int J Gynecol Cancer 2011, 21:1078-1083.
• [28]Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M: Clinical significance of Trop-2 expression in colorectal cancer. Clin Cancer Res 2006, 12:3057-3063.
• [29]Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G: High expression of Trop-2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008, 99(8):1290-1295.
• [30]Fong D, Spizzo G, Gostner JM, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G: Trop-2, a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mol Pathol 2008, 21:186-191.
• [31]Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, Ofner D, Fong D: Trop-2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009, 62:152-158.
• [32]Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2010, 46:944-953.
• [33]R Development Core Team (2012): R-A language and environment for statistical computing. http://www.R-project.org webcite
• [34]Punt C, Buyse M, Köhne C, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L, Sobrero A, Douillard J: Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007, 99:998-1003.
• [35]Sargent D, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A: Disease-free survival versus overall survival as a primary endpoints for adjuvant colon cancer studies: individual data from 20898 patients on 18 randomized trials. J Clin Oncol 2005, 23:8864-8670.
• [36]Cubas R, Zhang S, Li M, Chen C, Yao Q: Trop-2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Molec Cancer 2010, 9:253-265. BioMed Central Full Text
• [37]Cubas R, Li M, Chen C, Yao Q: Trop2-A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009, 1796:309-314.
• [38]Wang J, Day R, Dong Y, Weintraub SJ, Michel L: Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008, 7:280-285.
• [39]Ripani E, Sacchetti A, Corda D, Alberti S: Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998, 76(5):671-6.
• [40]Whitaker M: Larman: Calcium and mitosis. Semin Cell Devel Biol 2001, 12:53-58.
• [41]Meloche S, Pouyssegur J: The ERK 1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to-S-phase transition. Oncogene 2007, 26:3227-3239.
• [42]Boucher M, Morisset J, Vachon PH, Reed JC, Lainé J, Rivard N: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-Xl, and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000, 79:355-639.
• [43]El Sewedy T, Fornaro M, Alberti S: Cloning of the murine Trop2 gene- conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop2. Int J Cancer 2008, 75:324-30.
• [44]Basu A, Goldenberg DM, Stein R: The epithelial/carcinoma antigen EGP-1, recognized b monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 1995, 62:472-479.
• [45]Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, Lange RD, Weidle UH, Piantelli M, Alberti S: Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2012.
• [46]Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R, Piantelli M, Alberti S: The Trop-2 signalling network in cancer growth. Oncogene 2012.
• [47]Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M, Alberti S: A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 2008, 68:8113-8121.
• [48]Gan L, Liu P, Lu H: Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death Differ 2009, 16:1408-1417.
• [49]Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON: Trop-2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci 2008, 105:20882-20887.
• [50]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
• [51]Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J, et al.: Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 3:650-633.
• [52]Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM, Yang PC: TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med 2012, 4(6):472-85.
• [53]Chieng DC, Rodriguez-Buford C, Grizzle WA: Role of immunohistochemical expression of Lewis Y antigen in ovarian carcinoma. In Immunohistochemistry and In Situ Hybridization of Human Carcinomas, Vol 4. Edited by Hayat MA. Burlington, MA: Elsevier Academic Press; 2006:465-471.
• [54]Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE: Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004, 3:960-969.
• [55]Brown AK, Madom L, Moore R, Granai CO, DiSilvestro P: The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes. Gynecol Oncol 2007, 105:55-58.
• [56]Levenback CF: Status of sentinel lymph node biopsy in gynecological cancers. Ann Surg Oncol 2008, 15:18-20.
• [57]Koyuncuoglu M, Okyay E, Saatli B, Olgan S, Akin M, Saygili U: Tumor budding and e-cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer? Gynecol Oncol 2012, 125:208-213.
• [58]Mhawech-Fauceglia P, Wang D, Lele S, Frederick PJ, Pejovic T, Liu S: Claudin-7 and moesin in endometrial adenocarcinoma-aretrospective study of 265 patients. BMC Research Notes 2012, 5:65-71. BioMed Central Full Text